Fifth Third Bancorp
TRVI icon

Fifth Third Bancorp’s Trevi Therapeutics TRVI Stock Holding History

Fifth Third Bancorp’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Buy
260,644
+132,319
+103% +$1.92M 0.01% 797
2026
Q1 		$1.53M Buy
+128,325
New +$1.44M ﹤0.01% 1371
2020
Q2 		– Sell
-1,000
Closed -$3K – 2248
2020
Q1 		$3K Buy
+1,000
New +$4.54K ﹤0.01% 1950

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Fifth Third Bancorp's TRVI Position: Q2 2026 in Review

Fifth Third Bancorp increased its Trevi Therapeutics (TRVI) stake by 103% in Q2 2026, buying an estimated $1.92M and bringing the position to 260,644 shares worth $4.86M. The position accounts for 0.01% of the portfolio, ranked #797.

Fifth Third Bancorp first reported a position in TRVI in Q1 2020 and has held it in 3 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Fifth Third Bancorp held 260,644 shares of Trevi Therapeutics worth $4.86M as of Q2 2026.
  • Fifth Third Bancorp bought 132,319 Trevi Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Trevi Therapeutics made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #797 holding.
  • Fifth Third Bancorp first reported a position in Trevi Therapeutics in Q1 2020 and has held it in 3 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.